SCHEMBL1019779

SCHEMBL1019779

Nc1cccc(-c2ccno2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 5/20 0.51
CYP19A1 P11511 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
MEN1 O00255 3/20 0.47
PSIP1 O75475 1/20 0.47
AXL P30530 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
MAOA P21397 1/20 0.47
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
NOTUM Q6P988 1/20 0.46
MECP2 P51608 1/20 0.44
RAB9A P51151 2/20 0.44
CYP3A4 P08684 2/20 0.41
CYP17A1 P05093 1/20 0.41
CYP11B1 P15538 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30148417 1.00 MAP4K4 (0.51) MAP4K4CYP19A1CYP1A2CYP2C9CYP2C19
SCHEMBL1010173 0.78 KDM4E (0.60) CYP19A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL5648256 0.77 HSD17B1 (0.51) CYP19A1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL3931856 0.77 RAB9A (0.69) MAP4K4CYP19A1CYP1A2CYP2C9CYP2C19
SCHEMBL2278361 0.77 MEN1 (0.51) CYP19A1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL9188823 0.77 NOTUM (0.60) CYP19A1CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL27344998 0.77 CYP1A2 (0.49) CYP19A1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL16412256 0.76 NOTUM (0.44) MAP4K4CYP19A1CYP1A2CYP2C9CYP2C19
SCHEMBL1351742 0.75 NOTUM (0.63) CYP19A1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL3195754 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US claimed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN claimed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
US-11091488-B2 1-cyano-pyrrolidine derivatives as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-08-17 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
US-20200262838-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2020-08-20 US disclosed
EP-3383859-B1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2020-04-29 EP disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
EP-3383859-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30. Mission Therapeutics Limited (GB) 2018-10-10 EP disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
EP-1963287-A1 GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-09-03 EP disclosed
CN-101232863-A Agent for improving hair tension and toughness and cosmetic for hair SHISEIDO CO LTD (JP) 2008-07-30 CN disclosed
US-7348322-B2 Glucocorticoid receptor modulators as antiinflammatory agents ROCHE PALO ALTO LLC (US) 2008-03-25 US disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed
US-20070135427-A1 Glucocorticoid receptor modulators as antiinflammatory agents ROCHE PALO ALTO LLC 2007-06-14 US disclosed
WO-2007065828-A1 GLUCOCORTICOID RECEPTOR MODULATORS AS ANTIINFLAMMATORY AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-06-14 WO disclosed
CN-1019397-B The method for preparing diphosphonic acid derivative YAMANOUCHI PHARMA CO LTD (JP) 1992-12-09 CN disclosed
CN-88102021-A Diphosphonic acid derivative and contain the medicine of this derivative 1988-10-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091488-B2 1-cyano-pyrrolidine derivatives as inhibitors of USP30 USP30, USP1, USP20 MAP4K4 3516/4885CYP19A1 2690/4885CYP1A2 2595/4885
US-20070135427-A1 Glucocorticoid receptor modulators as antiinflammatory agents NR3C1, MC2R, NR3C2 MAP4K4 2064/4885CYP19A1 184/4885CYP1A2 388/4885
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAP4K4 2842/4885CYP19A1 497/4885CYP1A2 329/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAP4K4 2842/4885CYP19A1 497/4885CYP1A2 329/4885
US-20200262838-A1 1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30 USP30, USP1, USP20 MAP4K4 3516/4885CYP19A1 2690/4885CYP1A2 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.